BMS-986165

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Autoimmune Diseases

Conditions

Autoimmune Diseases

Trial Timeline

Apr 4, 2019 → Sep 25, 2019

NCT ID

NCT03956953

About BMS-986165

BMS-986165 is a phase 1 stage product being developed by Bristol Myers Squibb for Autoimmune Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03956953. Target conditions include Autoimmune Diseases.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06875960	Approved	Recruiting	Feb 27, 2026	Dec 1, 2026	Systemic Lupus Erythematosus (SLE)
NCT04613518	Phase 2	Completed	Mar 15, 2021	Nov 29, 2023	Colitis, Ulcerative
NCT04167462	Phase 3	Completed	Nov 25, 2019	Jan 7, 2022	Psoriasis
NCT03934216	Phase 2	Completed	Jul 1, 2019	Apr 4, 2023	Ulcerative Colitis
NCT03924427	Phase 3	Completed	Apr 10, 2019	Mar 24, 2021	Psoriasis
NCT03890770	Phase 1	Completed	Apr 4, 2019	Feb 13, 2020	Renal Impairment
NCT03956953	Phase 1	Completed	Apr 4, 2019	Sep 25, 2019	Autoimmune Diseases
NCT03920267	Phase 2	Completed	Mar 26, 2019	Mar 21, 2025	Systemic Lupus Erythematosus
NCT03890809	Phase 1	Completed	Feb 26, 2019	Nov 30, 2019	Liver Dysfunction
NCT03873415	Phase 1	Completed	Jan 25, 2019	May 1, 2019	Psoriasis
NCT03739788	Phase 1	Completed	Dec 5, 2018	Feb 11, 2019	Healthy Participants
NCT03599622	Phase 2	Terminated	Jul 16, 2018	Oct 23, 2023	Granulomatous Colitis
NCT03252587	Phase 2	Completed	Sep 21, 2017	Oct 28, 2021	Systemic Lupus Erythematosus
NCT03004768	Phase 1	Completed	Jan 26, 2017	Feb 27, 2017	Psoriasis

Competing Products

20 competing products in Autoimmune Diseases

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	77
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	52
Enteric-coated Mycophenolate Sodium	Novartis	Phase 3	77
Ianalumab + Placebo	Novartis	Phase 3	77
VAY736	Novartis	Phase 2/3	65
remibrutinib	Novartis	Phase 1	33
RO7049665	Roche	Phase 2	52
rituximab (Mabthera®) + Placebo	Roche	Phase 3	77
NovoMix 30 + Tablet treatment	Novo Nordisk	Pre-clinical	22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)	Swedish Orphan Biovitrum	Phase 2	51
branebrutinib + abatacept + branebrutinib placebo	Bristol Myers Squibb	Phase 2	51
Nivolumab	Bristol Myers Squibb	Phase 1	32
Fludarabine + Cyclophosphamide + Tocilizumab	Bristol Myers Squibb	Phase 1	32
BMS-986165 + Rosuvastatin	Bristol Myers Squibb	Phase 1	32
SAR445088	Sanofi	Phase 1	32
BIVV020	Sanofi	Phase 1	32
rilzabrutinib	Sanofi	Phase 2	51
rilzabrutinib + placebo	Sanofi	Phase 3	76

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved